1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2020, provides an overview of the Stroke (Cardiovascular) pipeline landscape.
Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 43, 23, 3, 3, 139, 17 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 33 and 6 molecules, respectively.
Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Stroke - Overview
- Stroke - Therapeutics Development
- Stroke - Therapeutics Assessment
- Stroke - Companies Involved in Therapeutics Development
- Stroke - Drug Profiles
- Stroke - Dormant Projects
- Stroke - Discontinued Products
- Stroke - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Stroke, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Stroke - Pipeline by AbbVie Inc, H2 2020
- Stroke - Pipeline by Acorda Therapeutics Inc, H2 2020
- Stroke - Pipeline by Acticor Biotech SAS, H2 2020
- Stroke - Pipeline by Admirx Inc, H2 2020
- Stroke - Pipeline by advanceCor GmbH, H2 2020
- Stroke - Pipeline by Advanced BioMatrix Inc, H2 2020
- Stroke - Pipeline by AegisCN LLC, H2 2020
- Stroke - Pipeline by Aegle Therapeutics Corp, H2 2020
- Stroke - Pipeline by Affibody AB, H2 2020
- Stroke - Pipeline by Allife Medical Science and Technology Co Ltd, H2 2020
- Stroke - Pipeline by Allosteros Therapeutics Inc, H2 2020
- Stroke - Pipeline by Anavex Life Sciences Corp, H2 2020
- Stroke - Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2020
- Stroke - Pipeline by Annovis Bio Inc, H2 2020
- Stroke - Pipeline by Anthos Therapeutics Inc, H2 2020
- Stroke - Pipeline by AntiRadical Therapeutics LLC, H2 2020
- Stroke - Pipeline by Antoxis Ltd, H2 2020
- Stroke - Pipeline by Zhittya Genesis Medicine Inc, H2 2020
- Stroke - Pipeline by Zocere Inc, H2 2020
- Stroke - Pipeline by ZyVersa Therapeutics Inc, H2 2020
- Stroke - Pipeline by ZZ Biotech LLC, H2 2020
- Stroke - Dormant Projects, H2 2020
- Stroke - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Stroke, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Acorda Therapeutics Inc
- Acticor Biotech SAS
- Admirx Inc
- advanceCor GmbH
- Advanced BioMatrix Inc
- AegisCN LLC
- Aegle Therapeutics Corp
- Affibody AB
- Allife Medical Science and Technology Co Ltd
- Allosteros Therapeutics Inc
- Anavex Life Sciences Corp
- Ankasa Regenerative Therapeutics Inc
- Annovis Bio Inc
- Anthos Therapeutics Inc
- AntiRadical Therapeutics LLC
- Antoxis Ltd
- Apellis Pharmaceuticals Inc
- Aposcience AG
- APT Therapeutics Inc
- AptaTargets SL
- AriBio
- ArmaGen Inc
- Aronora Inc
- Artelo Biosciences Inc
- ArunA Biomedical Inc
- Asta Pharmaceuticals Co Ltd
- AstraZeneca Plc
- Athersys Inc
- Aurum Biosciences Ltd
- Australia Medical Industries Pty Ltd
- Avilex Pharma ApS
- Axolo Pharma Inc
- AZTherapies Inc
- Band Therapeutics LLC
- Bayer AG
- Baylx Inc
- Beijing Yinfeng Dingcheng Bioengineering Co Ltd
- Bilix Co Ltd
- BioAxone BioSciences Inc
- Biogen Inc
- Boehringer Ingelheim International GmbH
- Bopin (Shanghai) Biomedical Technology Co Ltd
- Brain-Gen LLC
- Bristol-Myers Squibb Co
- Celltrion Inc
- Cenyx Biotech Inc
- Cerebrum Therapeutics Inc
- CHA Biotech Co Ltd
- China Resources Emde Biological Pharmaceutical Co Ltd
- Cogentis Therapeutics Inc
- CohBar Inc
- Constant Therapeutics LLC
- Creative Medical Technology Holdings Inc
- Crioestaminal Saude e Tecnologia SA
- CSPC Pharmaceutical Group Ltd
- Curacle Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- DeckTherapeutics Inc
- Deha Pharmaceutical LLC
- DiaMedica Therapeutics Inc
- Diffusion Pharmaceuticals Inc
- Edvince AB
- Eight Plus One Pharmaceutical Co Ltd
- EIP Pharma LLC
- Emerald Organic Products Inc
- Epigen Biosciences Inc
- Epygen Biotech Pvt Ltd
- Ever Supreme Bio Technology Co Ltd
- Evgen Pharma Plc
- eXithera Pharmaceuticals Inc
- Exscien Corp
- Fortuna Fix Inc
- Freeox Biotech SL
- FUJIFILM Toyama Chemical Co Ltd
- GABA Therapeutics Inc
- Genentech USA Inc
- Genervon Biopharmaceuticals LLC
- Glucox Biotech AB
- GNT Pharma Co Ltd
- Guangzhou Cellprotek Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Guangzhou Recomgen Biotech Co Ltd
- Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
- Gwoxi Stem Cell Applied Technology Co Ltd
- Haimen Shengyuan Stem Cell Technology Co Ltd
- Hefei Industrial Pharmaceutical Institute Co Ltd
- Hefei Medical & Pharmaceutical Co Ltd
- Hemostemix Inc
- Hibernaid Inc
- Hillhurst Biopharmaceuticals Inc
- Hope Biosciences LLC
- HSRx Group
- Immunwork Inc
- Instituto Biomar SA
- International Stem Cell Corp
- Io Therapeutics Inc
- JCR Pharmaceuticals Co Ltd
- Jeil Pharmaceutical Co Ltd
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Ouwei Pharmaceutical Co Ltd
- Jiangsu Simcere Pharmaceutical Co Ltd
- JT Pharmaceuticals Inc
- Kai Nuo Bio Sci Co Ltd
- Kyoto Drug Discovery & Development Co Ltd
- Les Laboratoires Servier SAS
- Lixte Biotechnology Holdings Inc
- LTT Bio-Pharma Co Ltd
- Lumosa Therapeutics Co Ltd
- M et P Pharma AG
- Mapreg SAS
- Marizyme Inc
- Meridigen Biotech Co Ltd
- MetiMedi Pharmaceuticals Co Ltd
- Mitoconix Bio Ltd
- Modulation Therapeutics Inc
- NC Medical Research Inc
- NervGen Pharma Corp
- NeuExcell Therapeutics Inc
- Neuraly Inc
- Neuren Pharmaceuticals Ltd
- Neurexis Therapeutics Inc
- NeurExo Sciences LLC
- Neurodon LLC
- NeuroFix Therapeutics LLC
- NeuroNascent Inc
- NeurOp Inc
- NeuroTrauma Sciences LLC
- Neurotrope Bioscience Inc
- New World Laboratories Inc
- Nipro Corp
- NoNO Inc
- Novago Therapeutics AG
- Novartis AG
- NuvOx Pharma LLC
- Nyrada Inc
- Omniox Inc
- OTR3 SAS
- Paracelsus Neuroscience I LLC
- Park Active Molecules
- Pharmagenesis Inc
- PharmatrophiX Inc
- Pharmazz Inc
- Pharmicell Co Ltd
- Phoenix Biotechnology Inc
- PhytoHealth Corp
- Prediction BioSciences SAS
- Primary Peptides Inc
- Protheragen Inc
- Q Therapeutics Inc
- Regenera Pharma Ltd
- Regeneron Pharmaceuticals Inc
- RegeneRx Biopharmaceuticals Inc
- ReNetX Bio
- ReNeuron Group Plc
- Rubicon Biotechnology Inc
- Saillant Therapeutics BV
- Saje Pharma LLC
- SanBio Company Limited
- Saneron CCEL Therapeutics Inc
- Saniona AB
- Sansho Co Ltd
- Savara Inc
- Seneca Biopharma Inc
- Sentan Pharma Inc
- Shanghai Angecon Biotechnology Co Ltd
- Shanghai SIMR Biotech Co Ltd
- Shanghai Zhimeng Biopharma Inc
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Shimao Tianjie Pharmaceutical (Jiangsu) Co Ltd
- Shin Poong Pharm Co Ltd
- Shionogi & Co Ltd
- Stemedica Cell Technologies Inc
- Stemetix Inc
- Stream Biomedical Inc
- SunBio Inc
- Suzhou Auzone Biological Technology Co Ltd
- Suzhou Pharmavan Cancer Research Center Co Ltd
- Suzhou Ribo Life Sciences Co Ltd
- TagCyx Biotechnologies
- TaiGen Biotechnology Co Ltd
- Tasly Pharmaceutical Group Co Ltd
- Techfields Pharma Co Ltd
- The Cell Factory BVBA
- TheraSource LLC
- Theratome Bio Inc
- Thrombolytic Science International LLC
- TikoMed AB
- TMS Co Ltd
- Translational Sciences Inc
- Valin Technologies Ltd
- Vanworld Pharmaceutical (Rugao) Company Ltd
- Vect-Horus SAS
- Venturis Therapeutics Inc
- Verseon Corp
- Virogenomics BioDevelopment Inc
- Virtici LLC
- XBiotech Inc
- Xcelthera INC
- Xonovo Inc
- Yantai YenePharma Co Ltd
- YouCare Pharmaceutical Group Co Ltd
- Zensun (Shanghai) Sci & Tech Co Ltd
- Zhejiang Ausun Pharmaceutical Co Ltd
- Zhittya Genesis Medicine Inc
- Zocere Inc
- ZyVersa Therapeutics Inc
- ZZ Biotech LLC
